12/22/2025 | Press release | Distributed by Public on 12/22/2025 15:10
|
Delaware
|
000-41905
|
91-1911336
|
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(I.R.S. Employer
Identification Number)
|
|
☐
|
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c))
|
|
Title of each class
|
Trading
Symbol(s)
|
Name of each exchange on which registered
|
||
|
Common Stock, $0.001 par value
|
SAVA
|
NASDAQ Capital Market
|
|
Exhibit No.
|
Description
|
|
|
104
|
Cover Page Interactive Data File (embedded within the Inline XBRL document)
|
|
CASSAVA SCIENCES, INC.
|
|||
|
a Delaware corporation
|
|||
|
Date: December 22, 2025
|
|||
|
By:
|
/s/ ERIC J. SCHOEN
|
||
|
Eric J. Schoen
|
|||
|
Chief Financial Officer
|
|||